Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.12 | -$0.10 | -$0.11 |
| Q2 2026 | 1 | -$0.11 | -$0.11 | -$0.11 |
| Q3 2026 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q4 2026 | 1 | -$0.13 | -$0.13 | -$0.13 |
| Q1 2027 | 1 | -$0.10 | -$0.10 | -$0.10 |
| Q2 2027 | 1 | -$0.09 | -$0.09 | -$0.09 |
| Q3 2027 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q4 2027 | 1 | -$0.03 | -$0.03 | -$0.03 |
Applied Therapeutics Inc last posted its earnings results on Thursday, November 13th, 2025. The company reported $-0.13046 earnings per share for the quarter, topping analysts' consensus estimates of $-0.14097 by $0.01051. The company had revenue of 1.00 M for the quarter and had revenue of 455.00 K for the year. Applied Therapeutics Inc has generated $-1 earnings per share over the last year ($-0.76 diluted earnings per share) and currently has a price-to-earnings ratio of -0.83. Applied Therapeutics Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2025 | Q3 2025 | -$0.14 | -$0.13 | 0.01 | $333.33 K | $1.00 M |
| 08/13/2025 | Q2 2025 | -$0.17 | -$0.15 | 0.02 | $416.67 K | $0 |
| 05/13/2025 | Q1 2025 | N/A | -$0.15 | N/A | N/A | $0 |
| 04/14/2025 | Q4 2024 | N/A | $0.32 | N/A | N/A | $0 |
| 11/07/2024 | Q3 2024 | -$0.16 | -$0.48 | -0.32 | $75.00 K | $122.00 K |
| 08/07/2024 | Q2 2024 | -$0.16 | $0.02 | 0.18 | $2.50 M | $144.00 K |
| 05/09/2024 | Q1 2024 | -$0.16 | -$0.67 | -0.51 | N/A | $190.00 K |
| 03/06/2024 | Q4 2023 | -$0.19 | -$0.45 | -0.26 | N/A | $-667,000 |
| 11/09/2023 | Q3 2023 | -$0.24 | -$0.47 | -0.23 | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$0.27 | -$0.37 | -0.1 | N/A | $0 |
| 05/11/2023 | Q1 2023 | -$0.31 | -$0.18 | 0.13 | N/A | $10.66 M |
| 03/23/2023 | Q4 2022 | -$0.46 | -$0.12 | 0.34 | N/A | $0 |
| 11/09/2022 | Q3 2022 | -$0.48 | -$0.40 | 0.08 | N/A | $0 |
| 08/12/2022 | Q2 2022 | -$0.75 | -$1.28 | -0.53 | N/A | $0 |
| 05/12/2022 | Q1 2022 | -$0.83 | -$0.88 | -0.05 | N/A | $0 |
| 03/10/2022 | Q4 2021 | -$1.20 | -$1.05 | 0.15 | N/A | $0 |
| 11/12/2021 | Q3 2021 | N/A | -$1.09 | N/A | N/A | $0 |
| 08/12/2021 | Q2 2021 | N/A | -$0.99 | N/A | N/A | $0 |
| 05/11/2021 | Q1 2021 | N/A | -$1.00 | N/A | N/A | $0 |
| 03/18/2021 | Q4 2020 | N/A | -$0.98 | N/A | N/A | $0 |
In the previous quarter, Applied Therapeutics Inc (:APLT) reported $-0.13046 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.14097 by $0.01051.
The conference call for Applied Therapeutics Inc's latest earnings report can be listened to online.
The conference call transcript for Applied Therapeutics Inc's latest earnings report can be read online.
Applied Therapeutics Inc (:APLT) has a recorded annual revenue of $455.00 K.
Applied Therapeutics Inc (:APLT) has a recorded net income of $-105,624,000.Applied Therapeutics Inc has generated $-0.76 earnings per share over the last four quarters.
Applied Therapeutics Inc (:APLT) has a price-to-earnings ratio of -0.83 and price/earnings-to-growth ratio is -0.01.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED